drugset
drugset / Trial / NCT04113993

Bazedoxifene -Treatment for Women With Schizophrenia

NCT04113993 ↗

Phase 4 Recruiting 160 enrolled The Alfred Monash University · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To study the effect of adjunctive bazedoxifene - a selective estrogen receptor modulator (SERM) in a double blind, placebo-controlled adjunctive study in the treatment of women with schizophrenia. All patients receive standardized antipsychotic medication.

Timeline

Start
2019-10-07
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bazedoxifene Other / unclassified 40 mg Oral

Indications

schizoaffective disorder schizophrenia schizophreniform disorder